Orthofix International N.V. (NASDAQ:OFIX) CEO Brad Mason sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total value of $267,400.00. Following the transaction, the chief executive officer now directly owns 183,053 shares in the company, valued at $9,789,674.44. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of Orthofix International N.V. (NASDAQ OFIX) traded up $0.07 during midday trading on Thursday, hitting $54.22. The company had a trading volume of 99,525 shares, compared to its average volume of 149,435. The stock has a market cap of $981.01, a PE ratio of 35.17, a price-to-earnings-growth ratio of 2.67 and a beta of 0.15. Orthofix International N.V. has a 52 week low of $32.51 and a 52 week high of $54.73.

Orthofix International (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The company had revenue of $105.30 million for the quarter, compared to analysts’ expectations of $100.67 million. During the same period last year, the firm posted $0.36 EPS. Orthofix International’s revenue for the quarter was up 6.9% compared to the same quarter last year. equities analysts forecast that Orthofix International N.V. will post 1.61 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of OFIX. UBS Asset Management Americas Inc. bought a new position in Orthofix International during the 1st quarter worth approximately $229,000. Vanguard Group Inc. grew its position in Orthofix International by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 1,815,948 shares of the medical device company’s stock worth $69,278,000 after acquiring an additional 284,482 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Orthofix International by 2.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 779,771 shares of the medical device company’s stock worth $29,748,000 after acquiring an additional 20,473 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Orthofix International by 2.7% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 169,143 shares of the medical device company’s stock worth $6,453,000 after acquiring an additional 4,428 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Orthofix International by 834.2% during the 1st quarter. Bank of America Corp DE now owns 28,838 shares of the medical device company’s stock worth $1,100,000 after acquiring an additional 25,751 shares during the last quarter. Institutional investors and hedge funds own 94.59% of the company’s stock.

A number of equities analysts recently weighed in on OFIX shares. TheStreet raised Orthofix International from a “c+” rating to a “b-” rating in a report on Tuesday, August 8th. BidaskClub raised Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Jefferies Group reissued a “buy” rating and set a $55.00 price objective (up from $50.00) on shares of Orthofix International in a report on Thursday, August 10th. Zacks Investment Research raised Orthofix International from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Thursday, August 10th. Finally, BTIG Research set a $56.00 price objective on Orthofix International and gave the company a “buy” rating in a report on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Orthofix International has an average rating of “Buy” and a consensus price target of $54.42.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/30/insider-selling-orthofix-international-n-v-ofix-ceo-sells-5000-shares-of-stock.html.

About Orthofix International

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.